20 June 2013
Keywords: hybridon, starts, campto/antisense, trial, antisense, therapeutic, specialist
Article | 11 March 2002
US antisense therapeutic specialist Hybridon has initiated a Phase I/IIclinical trial to study the combination of its GEM 231 drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 March 2002
19 June 2013
© 2013 thepharmaletter.com